Securities class action filed against AeroVironment, adding litigation risk to SCAR and integration challenges

What happened

Rosen Law Firm announced a class action lawsuit on behalf of AVAV investors who purchased between June 25, 2025 and March 10, 2026, covering the period when the company completed its BlueHalo acquisition and later disclosed SCAR program termination and goodwill impairment. The lawsuit follows a 50%+ stock decline from the October 2025 high of $407 to below $200 by March 2026, triggered by the Space Force's SCAR reset and a $151.3M goodwill write-off. While the company had disclosed risks, the class action alleges that statements during the class period were materially misleading, particularly regarding the sustainability of SCDE backlog and integration of BlueHalo. This legal overhang compounds the existing investment thesis challenges: SCAR options worth $1.49B are no longer expected to be awarded, SCDE remains loss-making, and internal controls have material weaknesses. The lawsuit does not alter the fundamental business outlook but introduces potential settlement costs and management distraction, adding to the reasons to wait for clearer evidence of SCDE profitability and backlog recovery.

Implication

The class action lawsuit is a symptom of the severe stock decline and does not change the underlying wait-and-see thesis. However, it raises the bar for re-entry: investors should require not only SCDE profitability and new awards but also clarity on litigation outcomes. The lawsuit may pressure management to settle, which could create a near-term overhang or a buying opportunity if settled cheaply. For now, the risk/reward remains unfavorable with a WAIT rating and trim above $210, as the legal process will likely consume management attention and cash resources. The thesis now requires a lower entry point to compensate for the added legal uncertainty.

Thesis delta

The class action lawsuit shifts the investment thesis from purely operational and programmatic risk to include litigation risk, reducing the probability of a quick recovery and lowering the attractive entry price. Previously, the call hinged on SCDE profitability and SCAR replacement; now investors must also gauge the materiality of alleged misstatements and potential settlement costs, which could delay any positive catalyst.